Corinne Vannier
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Multiple Myeloma Research and Treatments, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research
Most-Cited Works
- → The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs(2009)1,686 cited
- → Zeb1 Regulates E-cadherin and Epcam (Epithelial Cell Adhesion Molecule) Expression to Control Cell Behavior in Early Zebrafish Development(2013)89 cited
- → Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model(2008)41 cited
- → ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer(2016)21 cited
- → Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO(2021)11 cited
- → First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial(2020)9 cited
- → Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non‐interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials(2021)7 cited
- → PERFORM: A Non-Interventional Study Assessing The Patients' Treatment Starting With 1L Palbociclib in HR+/HER2- ABC(2022)4 cited
- → Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study(2019)1 cited